LNDC
Landec Corporation
Set alert
52-week range unavailable
- Open
- 9.01
- Prev close
- 8.76
- Mkt cap
- 259.26M
- Vol
- 52.47K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 8.75
- High
- 9.01
- Forward P/E
- 38.09
- Beta
- 1.10
- Short ratio
- 4.61
- Inst. own
- 85.33%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Jan 4, 2023
- 50-d avg
- 8.89
- 200-d avg
- 10.04
- 1y target
- 13.75
Key statistics
- Market cap
- 259.26M
- Enterprise value
- 425.30M
- Trailing P/E
- 0.00
- Forward P/E
- 38.09
- PEG ratio
- -3.22
- Price / sales
- 1.38
- Price / book
- 2.68
- EPS (TTM)
- -2.17
- Beta
- 1.10
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -53.34%
- Revenue (TTM)
- 187.51M
- Revenue growth
- 4.10%
- Free cash flow
- -25.20M
- Total cash
- 4.31M
- Total debt
- 157.04M
- Return on equity
- -34.88%
- Shares outstanding
- 29.60M
- Short % of float
- 1.39%
- 50-day average
- 8.89
- 200-day average
- 10.04
Analyst view
Consensus: strong buy
- Target (low)
- 12.00
- Target (mean)
- 13.75
- Target (high)
- 16.00
- Strong buy1
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Jan 4, 2023
Expected Jan 4, 2023. Consensus EPS estimate -0.04.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jan 4, 2023 | Nov 1, 2022 | -0.02 | — | — | — |
| Oct 6, 2022 | Aug 1, 2022 | -0.12 | — | — | — |
| Aug 10, 2022 | May 1, 2022 | -0.02 | — | — | — |
| Apr 5, 2022 | Feb 1, 2022 | 0.00 | — | — | — |
| Jan 5, 2022 | Nov 1, 2021 | -0.08 | — | — | — |
| Sep 29, 2021 | Aug 1, 2021 | -0.11 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 7, 2022 | Barrington Research | main | — | Outperform |
| Aug 11, 2022 | Barrington Research | up | Market Perform | Outperform |
| Jul 20, 2022 | Stephens & Co. | init | — | Overweight |
| Apr 6, 2022 | Barrington Research | down | Outperform | Market Perform |
| Oct 4, 2021 | Roth Capital | main | — | Buy |
| Jul 30, 2021 | Roth Capital | main | — | Buy |
About Landec Corporation
Landec Corporation, together with its subsidiaries, designs, develops, manufactures, and sells differentiated health and wellness products for food and biomaterials markets in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. The Curation Foods segment engages in processing, marketing, and selling of olive oils and wine vinegars under the O brand; and guacamole and avocado food products under the Yucatan and Cabo Fresh brands, as well as various private labels. Landec Corporation was incorporated in 1986 and is headquartered in Santa Maria, California.
- Sector
- Healthcare
- Industry
- Drug Manufacturers—Specialty & Generic
- Country
- United States
- Website
- landec.com
News
- ROSEN, NATIONAL TRIAL LAWYERS, Encourages Lifecore Biomedical Inc. f/k/a Landec Corporation Investors to Inquire About Securities Class Action Investigation - LFCR, LNDC
- ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Lifecore Biomedical Inc. f/k/a Landec Corporation Investors to Inquire About Securities Class Action Investigation - LFCR, LNDC
- ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Lifecore Biomedical Inc. f/k/a Landec Corporation Investors to Inquire About Securities Class Action Investigation - LFCR, LNDC
- ROSEN, SKILLED INVESTOR COUNSEL, Encourages Lifecore Biomedical Inc. f/k/a Landec Corporation Investors to Inquire About Securities Class Action Investigation - LFCR, LNDC
- LFCR INVESTOR NEWS: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Lifecore Biomedical Inc. f/k/a Landec Corporation Investors to Inquire About Securities Class Action Investigation - LFCR, LNDC
- Landec Corporation (LNDC) Q1 2023 Earnings Call Transcript
- Landec (LNDC) Reports Q1 Loss, Tops Revenue Estimates
- Landec Corporation Revises First Quarter 2023 Earnings Conference Call for October 6, 2022 at 8:00 a.m. ET
- Landec Corporation Sets First Quarter 2023 Earnings Conference Call for October 5, 2022 at 2:00 p.m. PT
- 7 Small-Cap Stocks to Buy Before September Ends
Your note
Sign in to keep a note on LNDC — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARBAROSH CRAIG A | Director | Conversion of Exercise of derivative security | Jun 2, 2022 | 0 |
| CAROSELLA DEBORAH D | Director | Conversion of Exercise of derivative security | Jun 2, 2022 | 36,588 |
| EDWARDS JEFFREY L | Director | Stock Award(Grant) | Jun 2, 2022 | 12,457 |
| HALL JAMES G | Officer | Stock Award(Grant) | Aug 4, 2022 | 51,096 |
| HOUDE KATRINA LOVAS | Director | Stock Award(Grant) | Jun 2, 2022 | 22,696 |
| OBUS NELSON | Director | Stock Award(Grant) | Jun 2, 2022 | 51,477 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Wynnefield Capital Management LLC | 11.94% | 3,533,287 | 30.95M | Sep 29, 2022 |
| Legion Partners Asset Management, LLC | 9.94% | 2,940,340 | 25.76M | Sep 29, 2022 |
| Blackrock Inc. | 6.43% | 1,902,022 | 16.66M | Jun 29, 2022 |
| Cove Street Capital, LLC | 6.38% | 1,888,494 | 16.54M | Sep 29, 2022 |
| Dimensional Fund Advisors LP | 6.20% | 1,833,902 | 16.06M | Sep 29, 2022 |
| 22NW, LP | 5.93% | 1,755,161 | 15.38M | Sep 29, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Heartland Value Fund | 3.55% | 1,050,000 | 9.20M | Sep 29, 2022 |
| Vanguard Total Stock Market Index Fund | 2.54% | 751,182 | 6.58M | Jun 29, 2022 |
| iShares Russell 2000 ETF | 1.85% | 547,914 | 4.80M | Sep 29, 2022 |
| DFA U.S. Small Cap Value Series | 1.57% | 465,282 | 4.08M | Jul 30, 2022 |
| Tocqueville Phoenix Fund | 1.31% | 388,700 | 3.41M | Sep 29, 2022 |
| Vanguard Extended Market Index Fund | 1.25% | 369,220 | 3.23M | Jun 29, 2022 |